 |
20 Diseases |  |
6 Trials |
|
6 Trials |  |
1040 News |  |
| «12...45678910111213141516 |
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion date, Trial initiation date, Trial termination, Trial primary completion date, Gram positive: Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis (clinicaltrials.gov) - Feb 19, 2018
P2, N=80, Terminated, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
Active, not recruiting --> Terminated | Trial completion date: Dec 2017 --> Dec 2017 | Initiation date: Mar 2016 --> Mar 2016 | Trial primary completion date: Dec 2017 --> Dec 2017
- | Zeven (dalbavancin) / RaQualia, AbbVie
New P4 trial, Gram positive: Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections (clinicaltrials.gov) - Feb 8, 2018
P4, N=50, Recruiting, Sponsor: Infectious Diseases Physicians, Inc.
- | Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open, Trial initiation date: Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients (clinicaltrials.gov) - Jan 24, 2018
P4, N=10, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Terminated | Trial completion date: Dec 2017 --> Dec 2017 | Initiation date: Mar 2016 --> Mar 2016 | Trial primary completion date: Dec 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> May 2017
- | Zeven (dalbavancin) / RaQualia, AbbVie
Trial initiation date: Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients (clinicaltrials.gov) - Jan 17, 2018
P4, N=10, Not yet recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> May 2017 Initiation date: Aug 2017 --> Feb 2018
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P4 trial: Hospital Avoidance Strategies for ABSSSI (clinicaltrials.gov) - Dec 14, 2017
P4, N=120, Not yet recruiting, Sponsor: Washington University School of Medicine
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial termination, Trial primary completion date: Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis (clinicaltrials.gov) - Oct 24, 2017
P2, N=2, Terminated, Sponsor: Allergan
Initiation date: Aug 2017 --> Feb 2018 N=150 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Aug 2017; Study stopped due to business reasons.
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial termination, Trial primary completion date, Gram positive: Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis (clinicaltrials.gov) - Sep 20, 2017
P2, N=1, Terminated, Sponsor: Allergan
N=150 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Aug 2017; Study stopped due to business reasons. N=100 --> 1 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Aug 2017; Business decision outlined by the corporation.
- |||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Aug 22, 2017
P4, N=86, Recruiting, Sponsor: Allergan
N=100 --> 1 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Aug 2017; Business decision outlined by the corporation. Active, not recruiting --> Recruiting
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment closed: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Aug 9, 2017
P4, N=86, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment closed, Trial primary completion date, Gram positive: Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis (clinicaltrials.gov) - Aug 8, 2017
P2, N=80, Active, not recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P4 trial: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Jul 27, 2017
P4, N=86, Not yet recruiting, Sponsor: Allergan
- || Zeven (dalbavancin) / RaQualia, AbbVie
Trial primary completion date: Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Jul 17, 2017
P4, N=322, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Sep 2017 --> Jun 2018
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial primary completion date: Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection (clinicaltrials.gov) - Jul 6, 2017
P1, N=12, Recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
Trial primary completion date: Sep 2017 --> Jun 2018 N=24 --> 12 | Trial primary completion date: May 2017 --> May 2020
- |||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open, Trial initiation date, Trial primary completion date, Gram positive: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (clinicaltrials.gov) - Jun 7, 2017
P3, N=300, Recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
N=24 --> 12 | Trial primary completion date: May 2017 --> May 2020 Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2017 | Trial primary completion date: Apr 2018 --> Jan 2019
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P2 trial: Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis (clinicaltrials.gov) - May 10, 2017
P2, N=150, Not yet recruiting, Sponsor: Allergan
- |||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open, Gram positive: Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis (clinicaltrials.gov) - May 8, 2017
P2, N=100, Recruiting, Sponsor: Allergan
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Mar 2017 | Trial primary completion date: Apr 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P2 trial, Gram positive: Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis (clinicaltrials.gov) - Mar 27, 2017
P2, N=100, Not yet recruiting, Sponsor: Allergan
- | Zeven (dalbavancin) / RaQualia, AbbVie
Phase classification: Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients (clinicaltrials.gov) - Mar 6, 2017
P4, N=10, Not yet recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P4
- |||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open: Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Dec 12, 2016
P4, N=322, Recruiting, Sponsor: Allergan
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P4 trial: Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (clinicaltrials.gov) - Nov 13, 2016
P4, N=322, Not yet recruiting, Sponsor: Allergan
- Zeven (dalbavancin) / RaQualia, AbbVie
New trial: Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=10, Not yet recruiting, Sponsor: University of Colorado, Denver
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial withdrawal, Gram positive: AHOM: Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis (clinicaltrials.gov) - Sep 23, 2016
P3, N=0, Withdrawn, Sponsor: Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Not yet recruiting --> Recruiting N=285 --> 0 | Not yet recruiting --> Withdrawn
- || Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial, Gram positive: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (clinicaltrials.gov) - Jun 28, 2016
P3, N=300, Not yet recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
- Zeven (dalbavancin) / RaQualia, AbbVie
Phase classification: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Jun 2, 2016
P3b, N=698, Completed, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
N=285 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P3 --> P3b
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open: Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection (clinicaltrials.gov) - May 13, 2016
P1, N=24, Recruiting, Sponsor: Durata Therapeutics International B.V., an Allergan Affiliate
Phase classification: P3 --> P3b Not yet recruiting --> Recruiting
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment open, Gram positive: Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis (clinicaltrials.gov) - May 13, 2016
P2, N=80, Recruiting, Sponsor: Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zeven (dalbavancin) / RaQualia, AbbVie
Trial initiation date, Trial primary completion date, Gram positive: AHOM: Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis (clinicaltrials.gov) - Feb 29, 2016
P3, N=285, Not yet recruiting, Sponsor: Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Not yet recruiting --> Recruiting Initiation date: Mar 2015 --> Mar 2016 | Trial primary completion date: Mar 2018 --> Oct 2018
- Zeven (dalbavancin) / RaQualia, AbbVie
New P1 trial: Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection (clinicaltrials.gov) - Feb 23, 2016
P1, N=24, Not yet recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
- | Zeven (dalbavancin) / RaQualia, AbbVie
New P2 trial, Gram positive: Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis (clinicaltrials.gov) - Feb 18, 2016
P2, N=80, Not yet recruiting, Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: A P3 Comparator Trial in Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Jan 22, 2016
P3, N=0, Withdrawn, Sponsor: Durata Therapeutics Inc., a subsidiary of Allergan plc
Initiation date: Mar 2015 --> Mar 2016 | Trial primary completion date: Mar 2018 --> Oct 2018 N=438 --> 0 | Initiation date: Jan 2015 --> Nov 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Nov 2016
- ||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Aug 11, 2015
P3, N=698, Completed, Sponsor: Durata Therapeutics, Inc.
N=438 --> 0 | Initiation date: Jan 2015 --> Nov 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Nov 2016 Active, not recruiting --> Completed
- | Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion, Trial primary completion date: A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. (clinicaltrials.gov) - Jun 23, 2015
P1, N=36, Completed, Sponsor: Durata Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment closed: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Feb 12, 2015
P3, N=698, Active, not recruiting, Sponsor: Durata Therapeutics, Inc.
Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2015 Recruiting --> Active, not recruiting
- Zeven (dalbavancin) / RaQualia, AbbVie
Trial primary completion date: A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. (clinicaltrials.gov) - Jan 28, 2015
P1, N=36, Recruiting, Sponsor: Durata Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Oct 2015
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial, Gram positive: AHOM: Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis (clinicaltrials.gov) - Jan 26, 2015
P3, N=285, Not yet recruiting, Sponsor: Durata Therapeutics, Inc.
- ||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Dec 6, 2014
P3, N=698, Recruiting, Sponsor: Durata Therapeutics, Inc.
Trial primary completion date: Jun 2014 --> Oct 2015 N=410 --> 698
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial: A P3 Comparator Trial in Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Oct 22, 2014
P3, N=438, Not yet recruiting, Sponsor: Durata Therapeutics, Inc.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Apr 29, 2014
P3, N=410, Recruiting, Sponsor: Durata Therapeutics, Inc.
- | Zeven (dalbavancin) / RaQualia, AbbVie
New P1 trial: A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. (clinicaltrials.gov) - Sep 17, 2013
P1, N=36, Recruiting, Sponsor: Durata Therapeutics, Inc.
- ||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 4, 2012
P3, N=739, Completed, Sponsor: Durata Therapeutics, Inc.
N=410 --> 698 Recruiting --> Completed
- ||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Sep 9, 2012
P3, N=573, Completed, Sponsor: Durata Therapeutics, Inc.
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Sep 7, 2011
P3, N=739, Completed, Sponsor: Durata Therapeutics, Inc.